As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research […]
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Blood and Marrow Transplant Clinical Trials Network Clinical Program Manager Mykala Heuer, BSN, RN, outlines highlights in the agenda, including discussions on operations, empowering coordinators,…
Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into community oncology practices.
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
